Literature DB >> 7788533

Acute pancreatitis. Medical management.

C E Forsmark1, P P Toskes.   

Abstract

The medical management of acute pancreatitis is primarily supportive and involves making the patient nulla per os, providing adequate intravenous hydration, and controlling pain with analgesics. Systems to identify patients with severe pancreatitis at risk for morbidity and mortality are available but require supplementation with frequent, experienced clinical observation. A number of modalities to inhibit pancreatic secretion or pancreatic proteases have not been successful in clinical trials, although larger studies in patients with more severe pancreatitis are required to ultimately assess their effectiveness. The empiric use of imipenem and long-term peritoneal lavage in patients with severe or necrotizing pancreatitis appear promising but further studies are needed. The removal of impacted gallstones in patients with severe pancreatitis or cholangitis is useful, provided an expert endoscopist is available. Improvements in our ability to document pancreatic infection early by CT-directed aspiration have markedly improved our ability to manage pancreatic infection.

Entities:  

Mesh:

Year:  1995        PMID: 7788533

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  13 in total

Review 1.  High-mobility group box 1 protein and its role in severe acute pancreatitis.

Authors:  Xiao Shen; Wei-Qin Li
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis.

Authors:  A C Windsor; S Kanwar; A G Li; E Barnes; J A Guthrie; J I Spark; F Welsh; P J Guillou; J V Reynolds
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

3.  The protective effects of rutaecarpine on acute pancreatitis.

Authors:  Lu Yan; Qing-Fu Li; Yan-Ting Rong; Yong-Heng Chen; Zhao-Hong Huang; Zhi-Zhi Wang; Jie Peng
Journal:  Oncol Lett       Date:  2017-12-20       Impact factor: 2.967

4.  Early nonenhanced abdominal computed tomography can predict mortality in severe acute pancreatitis.

Authors:  Austin L Spitzer; Ruedi F Thoeni; Anthony M Barcia; Michael T Schell; Hobart W Harris
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

5.  Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.

Authors:  C D Johnson; A N Kingsnorth; C W Imrie; M J McMahon; J P Neoptolemos; C McKay; S K Toh; P Skaife; P C Leeder; P Wilson; M Larvin; L D Curtis
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

6.  Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality.

Authors:  B J Ammori; P C Leeder; R F King; G R Barclay; I G Martin; M Larvin; M J McMahon
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

7.  Extrapancreatic organ impairment during acute pancreatitis induced by bile-pancreatic duct obstruction. Effect of N-acetylcysteine.

Authors:  Manuel A Manso; Laura Ramudo; Isabel De Dios
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

8.  Polymorphisms in tumour necrosis factor alpha (TNFalpha) gene in patients with acute pancreatitis.

Authors:  Gül Ozhan; Hakan T Yanar; Cemalettin Ertekin; Buket Alpertunga
Journal:  Mediators Inflamm       Date:  2010-04-14       Impact factor: 4.711

9.  Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis.

Authors:  Sakhawat H Rahman; Basil J Ammori; John Holmfield; Michael Larvin; Michael J McMahon
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

Review 10.  Acute pancreatitis: the substantial human and financial costs.

Authors:  J P Neoptolemos; M Raraty; M Finch; R Sutton
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.